Castle Biosciences (NasdaqGM:CSTL) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsCamilla Zuckero - Vice President, Investor Relations and Corporate AffairsCarlos Peniche - Former Equity Research AssociateDerek Maetzold - Founder, President, and CEOFrank Stokes - CFOThomas Heinzen - Managing Director in Healthcare Investment BankingConference Call ParticipantsAlex Vukasin - Healthcare Equity Research AnalystJosh R. Waldman - Equity Research AnalystMason Carrico - Research AnalystMat ...

Castle Biosciences (NasdaqGM:CSTL) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsCamilla Zuckero - Vice President, Investor Relations and Corporate AffairsCarlos Peniche - Former Equity Research AssociateDerek Maetzold - Founder, President, and CEOFrank Stokes - CFOThomas Heinzen - Managing Director in Healthcare Investment BankingConference Call ParticipantsAlex Vukasin - Healthcare Equity Research AnalystJosh R. Waldman - Equity Research AnalystMason Carrico - Research AnalystMat ...

Castle Biosciences (NasdaqGM:CSTL) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker6Good afternoon, and welcome to Castle Biosciences's fourth quarter and full year 2025 conference call. As a reminder, today's call is being recorded. We will begin today's call with opening remarks and introductions, followed by a question and answer session. I would like to turn the call over to Camilla Zuckero, Vice President, Investor Relations and Corporate Affairs.Speaker1Thank you, operator. Good afternoon, ...

Empowering people, informing care decisions February 2026 ©2026 Castle Biosciences 1 Disclaimers Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. These forward-looking statements include, but are not limited to, statements concerning: our positioning for continued grow ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K CASTLE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 77-0701774 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITI ...

2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2025.“We closed out an outst ...

Core Insights - Castle Biosciences announced the publication of a study demonstrating that its AdvanceAD-Tx test can effectively identify patients with moderate-to-severe atopic dermatitis who are more likely to respond positively to JAK inhibitor therapy compared to Th2-targeted therapies [1][2][8] Group 1: Study Findings - The AdvanceAD-Tx test identified approximately 30% of patients as having a JAK Inhibitor Responder Profile, who were 5.5 times more likely to achieve at least 90% improvement in Eczema Area and Severity Index (EASI-90) within three months compared to those on Th2-targeted therapies (45.5% vs. 8.3%, p=0.021) [3][6] - Patients with the JAK Inhibitor Responder Profile achieved a response nearly four times faster than those treated with Th2-targeted therapies (p=0.049) [3][6] - The study also indicated that patients with a JAK Inhibitor Responder Profile reported higher rates of "no itch" (45.5% vs. 8.3%, p=0.021) and remained flare-free by three months (54.5% vs. 16.7%, p=0.041) [6][8] Group 2: Clinical Implications - The findings suggest that aligning systemic therapy selection with an individual patient's molecular profile can streamline care, reduce unnecessary treatment changes, and accelerate meaningful clinical improvement [5][8] - The AdvanceAD-Tx test provides objective molecular insights that can help clinicians make more confident, evidence-based treatment decisions earlier in the patient journey [5][8] - Patients identified with a Th2 Molecular Profile showed no statistically significant differences in outcomes when treated with either JAK inhibitors or Th2-targeted therapies, emphasizing the importance of personalized treatment decisions [4][8] Group 3: Product Overview - AdvanceAD-Tx is a non-invasive gene expression profile test designed for patients aged 12 years and older with moderate-to-severe atopic dermatitis, evaluating 487 genes across 12 inflammatory and cutaneous biology pathways [2][6] - The test requires only lesional skin scrapings, eliminating the need for biopsies, and classifies patients into either a JAK Inhibitor Responder Profile or a Th2 Molecular Profile [2][7]

Core Viewpoint - Castle Biosciences, Inc. (CSTL) has experienced significant selling pressure, resulting in a 16.8% decline in stock price over the past four weeks, but analysts anticipate improved earnings in the near future [1] Group 1: Technical Analysis - The Relative Strength Index (RSI) is utilized to determine if CSTL is oversold, with a current RSI reading of 25.01 indicating potential for a trend reversal [2][5] - Stocks oscillate between overbought and oversold conditions, and the RSI helps identify when a stock's price may be due for a reversal, suggesting that CSTL may present an entry opportunity for investors [3] Group 2: Fundamental Indicators - Analysts have raised earnings estimates for CSTL by 13.5% over the last 30 days, indicating a strong consensus among sell-side analysts that could lead to price appreciation [7] - CSTL holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks, which further supports the potential for a turnaround in the near term [8]

Core Viewpoint - Castle Biosciences, Inc. will release its financial results for Q4 and the full year of 2025 on February 26, 2026, after market close [1] Group 1: Financial Results Announcement - The financial results will be discussed in a conference call and webcast at 4:30 p.m. Eastern time on the same day [1] - A live webcast of the conference call can be accessed through the company's Investor Relations page [2] - A replay of the webcast will be available after the conference call concludes [2] Group 2: Conference Call Access - To join the live conference call via phone, dial 1 833 470 1428 from the U.S. using access code 695618 [3] - International dial-in numbers are provided on a separate link, and the same access code is required [3] - A brief Q&A session will follow the management commentary [3] Group 3: Company Overview - Castle Biosciences is a leading diagnostics company focused on improving health through innovative tests that guide patient care [4] - The company specializes in dermatologic and gastroenterological diseases, developing personalized and clinically actionable solutions [4] - The company emphasizes empowering patients and clinicians through advanced molecular tests that support confident treatment planning [5]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Castle Biosciences, Inc. (CSTL) - CSTL currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The company has a Zacks Rank of 1 (Strong Buy), suggesting a favorable outlook based on historical performance metrics [3] Price Performance - CSTL shares have increased by 1.7% over the past week, while the Zacks Medical - Biomedical and Genetics industry has decreased by 0.35% during the same period [5] - Over the last month, CSTL's price change is 5.14%, significantly outperforming the industry's 0.96% [5] - In the last quarter, CSTL shares have surged by 74.1%, and over the past year, they have gained 59.06%, compared to the S&P 500's increases of 3.46% and 14.89%, respectively [6] Trading Volume - CSTL's average 20-day trading volume is 300,665 shares, which serves as a bullish indicator when combined with rising stock prices [7] Earnings Outlook - In the past two months, one earnings estimate for CSTL has increased, while none have decreased, leading to a consensus estimate rise from -$0.34 to -$0.27 [9] - For the next fiscal year, one estimate has moved upwards with no downward revisions, indicating positive earnings momentum [9] Conclusion - Given the strong performance metrics and positive earnings outlook, CSTL is positioned as a 1 (Strong Buy) stock with a Momentum Score of A, making it a compelling investment option [11]